Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Navin Pinto

Concepts (152)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Neuroblastoma
18
2026
177
5.600
Why?
Neoplasm Recurrence, Local
10
2026
1160
2.350
Why?
Immunotherapy, Adoptive
8
2026
356
2.060
Why?
Antineoplastic Combined Chemotherapy Protocols
9
2026
1998
1.200
Why?
B7 Antigens
3
2025
18
1.100
Why?
T-Lymphocytes
8
2026
2012
1.090
Why?
Drug Resistance, Neoplasm
4
2026
893
1.040
Why?
Neural Cell Adhesion Molecule L1
1
2026
3
0.980
Why?
B7-H1 Antigen
2
2019
245
0.940
Why?
Receptors, Antigen, T-Cell
3
2026
677
0.870
Why?
Cyclophosphamide
2
2024
275
0.840
Why?
Neoplasms
6
2024
2954
0.840
Why?
Salvage Therapy
3
2021
166
0.790
Why?
Medical Oncology
3
2025
345
0.710
Why?
Immunotherapy
1
2026
671
0.670
Why?
Infant
20
2026
10114
0.650
Why?
Rhabdomyosarcoma
1
2021
65
0.640
Why?
Child
28
2026
22693
0.600
Why?
N-Myc Proto-Oncogene Protein
3
2025
11
0.570
Why?
Prognosis
11
2025
4351
0.550
Why?
Child, Preschool
19
2026
11913
0.540
Why?
Lymphoma
1
2019
251
0.530
Why?
Programmed Cell Death 1 Ligand 2 Protein
1
2017
14
0.510
Why?
Antineoplastic Agents, Immunological
1
2019
200
0.510
Why?
Survival Rate
6
2026
2092
0.460
Why?
Programmed Cell Death 1 Receptor
1
2017
268
0.430
Why?
Gene Amplification
4
2025
116
0.430
Why?
Biomarkers, Tumor
3
2022
1339
0.420
Why?
Neoplasm Staging
5
2025
1488
0.420
Why?
Antibodies, Monoclonal, Humanized
1
2019
992
0.390
Why?
Brain Stem Neoplasms
2
2025
86
0.380
Why?
Melanoma
1
2019
765
0.370
Why?
Follow-Up Studies
7
2026
5439
0.360
Why?
Adolescent
18
2026
22557
0.360
Why?
3-Iodobenzylguanidine
4
2025
13
0.350
Why?
Central Nervous System Neoplasms
2
2025
177
0.350
Why?
Pharmacogenetics
2
2024
176
0.340
Why?
Fibrosarcoma
2
2022
22
0.340
Why?
Disease-Free Survival
3
2022
778
0.310
Why?
Soft Tissue Neoplasms
2
2022
133
0.300
Why?
Humans
36
2026
146342
0.290
Why?
Antigens, CD19
2
2026
137
0.260
Why?
Male
20
2026
73396
0.260
Why?
Stem Cell Transplantation
2
2018
190
0.250
Why?
Pediatrics
1
2015
1124
0.250
Why?
Female
20
2026
79499
0.240
Why?
Young Adult
10
2025
14330
0.220
Why?
Lymphoma, B-Cell
1
2026
150
0.210
Why?
Wilms Tumor
1
2025
91
0.200
Why?
Antibodies, Monoclonal
3
2026
1512
0.200
Why?
Vincristine
2
2021
148
0.200
Why?
Genes, myc
1
2023
45
0.190
Why?
Brain Neoplasms
2
2023
1325
0.190
Why?
Chromosome Deletion
1
2023
127
0.190
Why?
Survivors
2
2016
526
0.180
Why?
High-Throughput Nucleotide Sequencing
2
2023
539
0.180
Why?
Osteosarcoma
1
2023
100
0.180
Why?
Dactinomycin
1
2021
24
0.170
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2022
158
0.170
Why?
Adult
14
2026
41087
0.170
Why?
Kidney Neoplasms
1
2025
419
0.160
Why?
Whole Genome Sequencing
1
2021
183
0.160
Why?
Genomics
2
2023
853
0.160
Why?
Bone Neoplasms
1
2023
272
0.160
Why?
Proto-Oncogene Proteins c-ret
1
2020
41
0.150
Why?
Loss of Heterozygosity
1
2019
51
0.140
Why?
Cohort Studies
2
2019
6077
0.140
Why?
Treatment Outcome
3
2026
11821
0.140
Why?
Radionuclide Imaging
1
2018
116
0.140
Why?
Endocrine System Diseases
1
2018
35
0.140
Why?
Isotretinoin
1
2018
27
0.140
Why?
Leukapheresis
1
2018
27
0.140
Why?
Glioma
1
2022
425
0.130
Why?
Growth Disorders
1
2018
89
0.130
Why?
Glioblastoma
1
2021
350
0.130
Why?
Maximum Tolerated Dose
1
2018
217
0.130
Why?
Combined Modality Therapy
4
2025
1271
0.120
Why?
Prospective Studies
4
2022
8123
0.120
Why?
Immunoenzyme Techniques
1
2017
197
0.120
Why?
Polymorphism, Single Nucleotide
1
2024
2240
0.120
Why?
Image Interpretation, Computer-Assisted
1
2018
295
0.120
Why?
Hematopoietic Stem Cell Transplantation
1
2022
704
0.120
Why?
Neoadjuvant Therapy
1
2019
475
0.110
Why?
Neoplasms, Second Primary
1
2016
103
0.110
Why?
Leukemia
1
2018
246
0.110
Why?
Diffusion of Innovation
1
2015
96
0.110
Why?
International Cooperation
1
2015
193
0.110
Why?
Risk Factors
3
2019
10921
0.100
Why?
Interdisciplinary Communication
1
2015
200
0.100
Why?
Carcinoma, Non-Small-Cell Lung
1
2023
1195
0.100
Why?
Nuclear Proteins
1
2019
740
0.100
Why?
Logistic Models
1
2019
2126
0.100
Why?
Age of Onset
1
2015
558
0.100
Why?
Cancer Survivors
1
2018
348
0.090
Why?
Cooperative Behavior
1
2015
471
0.090
Why?
Retrospective Studies
4
2022
17438
0.080
Why?
ErbB Receptors
2
2025
636
0.080
Why?
Induction Chemotherapy
2
2022
87
0.080
Why?
Predictive Value of Tests
1
2015
2113
0.080
Why?
Leukemia, Myeloid, Acute
1
2016
702
0.070
Why?
Lung Neoplasms
1
2023
2675
0.070
Why?
Transplantation, Autologous
2
2022
306
0.070
Why?
Risk Assessment
2
2016
3712
0.070
Why?
RNA, Messenger
1
2017
2791
0.070
Why?
Infant, Newborn
2
2022
6460
0.070
Why?
Autografts
2
2018
56
0.070
Why?
Protein Kinase Inhibitors
2
2023
983
0.060
Why?
Time Factors
1
2015
7109
0.050
Why?
Area Under Curve
1
2024
335
0.050
Why?
Lactams
1
2023
28
0.050
Why?
Lactams, Macrocyclic
1
2023
51
0.050
Why?
Catheters
1
2023
73
0.050
Why?
Gene Fusion
1
2022
31
0.050
Why?
Aminopyridines
1
2023
128
0.040
Why?
Oncogenes
1
2022
113
0.040
Why?
Proto-Oncogene Proteins c-myc
1
2023
157
0.040
Why?
Microtubule-Associated Proteins
1
2022
187
0.040
Why?
Feasibility Studies
1
2026
1135
0.040
Why?
Neoplasm, Residual
1
2022
143
0.040
Why?
Chemokine CXCL10
1
2021
39
0.040
Why?
Chemokine CCL2
1
2021
112
0.040
Why?
Carcinogenesis
1
2022
226
0.040
Why?
Immunity
1
2021
141
0.040
Why?
Genetic Predisposition to Disease
2
2021
2488
0.040
Why?
Oncogene Fusion
1
2020
11
0.040
Why?
Molecular Targeted Therapy
1
2022
447
0.040
Why?
Base Sequence
1
2022
2123
0.040
Why?
Protein-Tyrosine Kinases
1
2022
429
0.040
Why?
Pyrazoles
1
2023
517
0.040
Why?
Egypt
1
2018
13
0.040
Why?
Busulfan
1
2018
15
0.040
Why?
Kaplan-Meier Estimate
1
2021
970
0.040
Why?
Melphalan
1
2018
43
0.030
Why?
Oncogene Proteins, Fusion
1
2020
213
0.030
Why?
Etoposide
1
2018
169
0.030
Why?
Xenograft Model Antitumor Assays
1
2021
930
0.030
Why?
Carboplatin
1
2018
168
0.030
Why?
Lymphocyte Count
1
2018
167
0.030
Why?
CD3 Complex
1
2018
113
0.030
Why?
Radiopharmaceuticals
1
2018
210
0.030
Why?
Precision Medicine
1
2021
462
0.030
Why?
Transplantation Conditioning
1
2018
193
0.030
Why?
Age Factors
1
2024
3347
0.030
Why?
Genetic Association Studies
1
2016
379
0.030
Why?
DNA Repair
1
2016
255
0.030
Why?
Dose-Response Relationship, Drug
1
2018
2022
0.030
Why?
Aged
2
2026
26432
0.020
Why?
Mutation
1
2023
4093
0.020
Why?
Disease Progression
1
2018
2867
0.020
Why?
Reproducibility of Results
1
2018
3416
0.020
Why?
Middle Aged
2
2026
36619
0.020
Why?
Incidence
1
2016
2936
0.020
Why?
Pinto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)